Document is current

Article History

Received: 17 August 2022

Accepted: 26 March 2023

First Online: 9 May 2023

Declarations

:

: Dr. Bernard Le Foll has obtained funding from Pfizer Inc. (GRAND Awards, including salary support) for investigator-initiated projects. Dr Le Foll has obtained funding from Indivior for a clinical trial sponsored by Indivior. Dr. Le Foll has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc. and study medication donations from Pfizer Inc. (varenicline for smoking cessation) and Bioprojet Pharma. He was also provided a coil for a transcranial magnetic stimulation (TMS) study from Brainsway. Dr. Le Foll has obtained industry funding from Canopy Growth Corporation (through research grants handled by the Centre for Addiction and Mental Health and the University of Toronto), Bioprojet Pharma, Alcohol Countermeasure Systems (ACS), Alkermes, and Universal Ibogaine. Lastly, Dr. Le Foll has received in-kind donations of nabiximols from GW Pharmaceuticals for past studies funded by CIHR and NIH.Dr. Le Foll has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and has been a consultant for Shinogi. He is supported by CAMH, Waypoint Centre for Mental Health Care, a clinician-scientist award from the Department of Family and Community Medicine of the University of Toronto and a Chair in Addiction Psychiatry from the Department of Psychiatry of the University of Toronto.Dr. Tony George is the chair of the scientific advisory committee of the Canadian Centre for Substance Use and Addiction (CCSA) and is compensated for cannabis-related policy work. Dr. George is also the co-principal editor of the journal <i>Neuropsychopharmacology</i>.